Chromadex Corp Stock OTC Bulletin Board
Stocks
CDXC
US1710771007
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 05-21 | NARB recommends Niagen modify/discontinue certain Tru Niagen NAD+ dietary supplement claims | RE |
| 05-07 | Niagen Bioscience, Inc., Q1 2026 Earnings Call, May 06, 2026 |
| Market Cap | 273M 239M 221M 207M 387M 25.75B 395M 2.65B 1.03B 12.73B 1.02B 1B 44.13B | P/E 2026 * |
14.9x | P/E 2027 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise Value | 273M 239M 221M 207M 387M 25.75B 395M 2.65B 1.03B 12.73B 1.02B 1B 44.13B | EV / Sales 2026 * |
1.92x | EV / Sales 2027 * | 1.64x |
| Free-Float |
70.75% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Chromadex Corp
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Fried
CEO | Chief Executive Officer | 66 | 01/06/2018 |
Ozan Pamir
DFI | Director of Finance/CFO | 35 | 21/10/2024 |
Mona Rosene
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Jaksch
CHM | Chairman | 57 | 22/06/2018 |
Robert Fried
BRD | Director/Board Member | 66 | 09/07/2015 |
Steven Rubin
BRD | Director/Board Member | 65 | 27/03/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.48% | +7.20% | -5.65% | +3.69% | 46.2B | |
| +2.19% | +11.71% | +393.31% | +609.31% | 38.71B | |
| +2.53% | +13.93% | +21.38% | -10.96% | 31.9B | |
| +1.65% | +3.61% | +16.04% | +55.24% | 31.12B | |
| -4.16% | -2.58% | +8.94% | +26.14% | 23.77B | |
| -0.32% | +12.96% | - | - | 16.2B | |
| +1.37% | +14.53% | +69.64% | +136.34% | 15.05B | |
| +1.00% | +10.30% | +13.31% | +23.36% | 13.74B | |
| +3.63% | +9.53% | +103.97% | +106.25% | 13.42B | |
| Average | +0.82% | +9.14% | +77.62% | +118.67% | 25.57B | |
| Weighted average by Cap. | +0.75% | +8.71% | +88.75% | +138.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 142M 125M 115M 108M 202M 13.42B 206M 1.38B 535M 6.63B 534M 523M 23B | 167M 146M 135M 126M 237M 15.75B 242M 1.62B 627M 7.78B 627M 613M 26.98B |
| Net income | 19.09M 16.74M 15.43M 14.45M 27.09M 1.8B 27.65M 185M 71.77M 890M 71.7M 70.14M 3.09B | 25.39M 22.27M 20.52M 19.21M 36.03M 2.4B 36.78M 247M 95.45M 1.18B 95.35M 93.27M 4.11B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NAGE Stock
- CDXC Stock
Select your edition
All financial news and data tailored to specific country editions
